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Abstract 
Background: To validate the association between country-of-birth and disparities in the stimulant use for ADHD 
among individuals in Western Australia.
Methods: Using linked data, a population-based retrospective cohort of individuals admitted to hospital before age 
25 years was followed through to identify having stimulants for ADHD in 2003–2007. Multivariate logistic and linear 
regressions were used to characterise associations between stimulants and country-of-birth, geographical remote-
ness and socioeconomic status.
Results: Of 679,645 individuals, 14,122 (2.1%) had a record of having stimulants for ADHD. Of these, 205 (1.5%) were 
born in Africa, Asia, Middle-East or South America, while 13,664 (96.8%) were born in Australia/New Zealand, Europe 
or North America. Individuals with traditionally non-Anglophonic backgrounds were around one-half as likely to have 
stimulants as individuals with Anglophonic backgrounds (OR = 0.53, 95% CI 0.46–0.61, p < 0.001). Non-Anglophones 
were an average of 2.7 years older than Anglophones at onset of having stimulants. Individuals from remote and dis-
advantaged backgrounds had stimulants at younger ages than individuals living in metropolitan areas and with least 
disadvantage.
Conclusions: The results highlight the importance of identifying factors underlying cultural differences in stimulant 
treatment for ADHD. Improving awareness of cultural variations may foster trust and rapport between patients and 
clinicians, and so better facilitate the appropriate and effective treatment of ADHD for each patient.
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Background
Attention deficit hyperactivity disorder (ADHD) is a 
commonly diagnosed chronic neurodevelopmental dis-
order in children and adolescents [1]. Psychostimulant 
medications are the most widely prescribed for ADHD 
treatment and the use of these medications has risen 
sharply in many parts of the world, particularly in Euro-
pean [2] and Western nations [3] over the last decade. 
In Australia, the stimulant prescribing rate for ADHD 
rose 72% between 2000 and 2011 [4], despite a signifi-
cant community concern that ADHD is over-diagnosed 
and over-treated [5]. It is surprising that we have lim-
ited information on cultural variations in prescription 
stimulant in Australia, and if cultural attitudes towards 
ADHD diagnosis and treatment influence medication 
use. In a previous study, Ghosh et al. [6] reported about 
83% lower stimulant use among ethnic minorities in 
Western Australia (WA) and attributed the disparities 
to parental country of birth differences. We examined 
differences in prescription stimulant between children 
and young adults born in traditionally Anglophonic and 
non-Anglophonic nations, in order to validate the earlier 
findings, but in this instance using the countries of birth 
of the children. Using a similar methodology, we hypoth-
esized that an individual’s country of birth would result 
in variation in stimulant use for ADHD. A more general 
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context for our research is the value we place on promot-




We conducted a population-based retrospective cohort 
study using the WA Data Linkage System and linked 
three state-wide statutory health databases: the Hos-
pital Morbidity Data Collection (HMDC) for inpatient 
separation, Monitoring of Drugs of Dependence System 
(MODDS) for stimulant records, and the Deaths Register 
[7]. The WA linkage system is well-known for high sensi-
tivity (95–99%) and specificity (98–99%) [7]. The cohort 
included all individuals, ages 0–25  years, who were 
admitted into a hospital for any reason during 1980–
2007, and followed through time to identify those who 
had a prescription stimulant for ADHD between 2003 
and 2007 (Fig. 1).
The HMDC is a core dataset routinely linked by the 
WA Data Linkage Branch to other administrative health 
data and is one of the largest data collections managed 
by the WA Department of Health (WADoH) [8]. In 
2012–2013, the HMDC comprised over 21 million elec-
tronic records of all public and private hospital stays in 
WA since 1970 [9]. The HMDC cohort was linked to 
the MODDS records to identify patients with an ADHD 
diagnosis and dispensed stimulant prescription. Under a 
WA Stimulant Regulatory Scheme enforced from 2003, 
public and private specialist medical practitioners in 
paediatrics, psychiatry, neurology and rehabilitation 
medicine were required by statute to obtain a stimulant 
prescriber number from the WADoH to be authorised to 
prescribe stimulant medications [10, 11]. The authorised 
prescribers were required to notify the WADoH of every 
commencement, alteration and termination of treat-
ment with stimulant medications in all community, out-
patient and inpatient settings. Similarly, it is a statutory 
requirement for all WA pharmacies to forward all infor-
mation related to the dispensing of the stimulants to the 
WADoH to be stored in the MODDS [12]. Under the reg-
ulations, stimulant medications could only be prescribed 
for the treatment of ADHD, brain damage, depression or 
narcolepsy [10]. For the purpose of this study, data were 
collected where stimulants were prescribed for ADHD 
treatment only. ADHD could be diagnosed according to 
either the International Classification of Diseases, 10th 
revision (ICD-10), or the Diagnostic and Statistical Man-
ual of Mental Disorders, fourth edition (DSM-IV) [11]. In 
Australia, short-acting dexamphetamine and long-acting 
methylphenidate are prescribed for ADHD treatment 
with stimulants, and considered cost-effective interven-
tions for ADHD, since these are subsidized by the Gov-
ernment under the Pharmaceutical Benefits Scheme [11, 
13].
WA is a state occupying the western third of the Aus-
tralian continent with an estimated population of 2.5 
million, around 11% of the national total in 2013 [14]. 
It was impossible to use census data to obtain a precise 
estimate of what proportion of the WA population aged 
0–25 years were hospitalised at least once during 1980–
2007. However, based on the relevant birth years of peo-
ple resident in 2007, our approximate estimate was in the 
order of 40%.
Variables and measurements
Geographical remoteness was scored according to the 
Accessibility/Remoteness Index of Australia of the Aus-
tralian Census, using whichever of the 1996, 2001 or 2006 
indices were closest to the year of cohort entry, and was 
grouped into three levels: metropolitan, rural and remote 
[15]. The index of relative socio-economic disadvantage 
from the socio-economic indexes for areas was used to 
categorise the study population into five levels of socio-
economic disadvantage ranging from most disadvan-
taged to least disadvantaged [15].
Individuals’ countries of birth were grouped under 
eight major geographical regions of the world accord-
ing to eHRAF [16] databases—an internationally rec-
ognised anthropological databases facilitating study of 
Hospital Morbidity Data Collection (1980-2007)
admission age 0-25 years
N=725596
Monitoring of Drugs of Dependence System 
2003-2007
Excluding:
• 5252 died before 2003











Fig. 1 Study design, sample selection and exclusion criteria. Hospital 
Morbidity Data Collection was linked to Monitoring of Drugs of 
Dependence dataset to identify individuals who were admitted into 
hospital for the first time at age 0–25, and then to match with indi-
viduals who had prescription stimulant for ADHD. The final number 
of the study population was stimulant 14,122 and non-stimulant 
665,523
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human culture, society and behaviour. The eight groups 
were: Asia, Europe, Africa, North-America, Middle-
East, Oceania (including Australia and New Zealand), 
Central-America and the Caribbean, and South America. 
The method used to classify country of birth are docu-
mented in detail in Ghosh et al. [6] paper where a pattern 
of reduced stimulant use was identified among indi-
viduals who were born in Africa, Asia, Middle-East or 
South America compared with those born in Australia/
New Zealand, Europe or North America. As a result, 
we aggregated country of birth into Higher Propensity 
National Origin (HPNO), including Australia/New Zea-
land, Europe and North America, and Lower Propensity 
National Origin (LPNO) status for rest of the countries. 
For the purposes of the current study we focused our 
comparison on country of birth based on an individual’s 
HPNO and LPNO status.
Statistical analysis
The outcome measure was at least one prescription stim-
ulant for ADHD dispensed during 2003–2007. Descrip-
tive statistics were performed for all study variables, 
including means and standard deviations obtained for 
continuous variables, and frequencies and percentages 
for categorical variables. Univariate and multivariate 
logistic regression models were used to examine factors 
associated with stimulant use. Individuals’ age for initial 
prescription stimulants between 2003 and 2007 were 
compared using multiple linear regression. Missing val-
ues where information was unknown for each variable 
were treated as a separate ‘unknown’ exposure category 
so that all subjects were included in the analyses. Individ-
uals who died prior to 2003 were excluded from the study 
sample. Individuals identified themselves as Aboriginals 
were also excluded from the analysis. This exclusion fol-
lowed the methods employed in a previous study due to 
likely cultural differences in the understanding of ADHD 
and attitudes towards medication between Aboriginals 
and non-Aboriginals [6].
Results
Of the 679,645 individuals admitted to hospital for the 
first time by the age 25  years, 14,122 (2.1%) received 
a prescription stimulant for ADHD treatment during 
2003–2007. The characteristics of the cohort are shown 
in Table  1. Of individuals who received stimulants, the 
majority of them (n = 13,664, 96.8%) were born in Aus-
tralia/New Zealand, North America or Europe, with 
fewer (n = 205, 1.5%) born in Africa, Asia, Middle-East or 
South America. Nearly 2% (n = 253) did not have coun-
try of birth information. Individuals in rural and remote 
parts of WA comprised 17% (n = 2401), compared with 
70% (n  =  9869) who resided in the metropolitan area. 
Another 13% had missing residential information. Nearly 
one half (n = 6650, 47%) came from the least socioeco-
nomically disadvantaged group, whilst 7% (n  =  1002) 
belonged to the most disadvantaged group. There were 
3.3 times more males receiving stimulant than females 
(76.7 vs. 23.3%).
Both univariate and multivariate models indicated that 
individuals with LPNO backgrounds were approximately 
half as likely to receive stimulants compared with those 
with HPNO backgrounds (OR 0.53, 95% CI 0.46–0.61, 
p  <  0.001) (Table  2). Females were 69% less likely to 
receive stimulants than males (OR 0.31, 95% CI 0.30–
0.32, p < 0.001). The odds of receiving a stimulant were 
significantly lower in those living in rural (OR 0.80, 95% 
CI 0.77–0.84) and remote areas (OR 0.43, 95% CI 0.38–
0.48) than in the metropolitan areas. At univariate level 
the odds for having stimulants was 1.8 times greater (OR 
1.08, 95% CI 1.01–1.15) in the less disadvantage group 
Table 1 Characteristics of the study population according 
to stimulant medication use for ADHD
HPNO includes Australia/New Zealand, Europe and North America, LPNO 
includes Africa, Asia, Middle East and South America




 Male 340,226 (51.1) 10,834 (76.7)
 Female 325,295 (48.9) 3288 (23.3)
 Unknown 2 (0.01)
Age at initial stimulant use between 2003 and 2007
 0–4 years – 108 (0.8%)
 5–12 – 7065 (50.0)
 13–17 – 3941 (27.9)
 ≥18 – 3008 (21.3)
HPNO/LPNO status
 HPNO 635,914 (95.6) 13,664 (96.8)
 LPNO 18,656 (2.8) 205 (1.5)
 Unknown 10,953 (1.6) 253 (1.8)
Geographical remoteness
 Metropolitan 421,764 (63.4) 9869 (69.9)
 Rural 111,860 (16.8) 2130 (15.1)
 Remote 26,302 (4.0) 271 (1.9)
 Unknown 105,597 (15.9) 1852 (13.1)
Social disadvantage
 Least disadvantaged 293,172 (44.1) 6650 (47.1)
 Less disadvantaged 141,043 (21.2) 2916 (20.6)
 Little disadvantaged 54,297 (8.2) 1198 (8.5)
 More disadvantaged 26,630 (4.0) 553 (3.9)
 Most disadvantaged 47,521 (7.1) 1002 (7.1)
 Unknown 102,860 (15.5) 1803 (12.8)
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than in the least disadvantaged, but the trend did not 
continue with greater levels of disadvantage. None of the 
examined disadvantaged group was a strong determinant 
of stimulant use after adjustment.
The mean age at onset of stimulants for those with a 
LPNO background was nearly three years older than in 
those with a HPNO background (14.98 vs. 12.27  years 
after adjustment, p  <  0.001) (Table  3). Males received 
stimulants at an average age of 12.78  years, about two 
years younger than females at 14.47  years. Individuals 
from rural and remote areas were also about one year 
younger than those from the metropolitan area. Similarly 
those from the least disadvantaged group were between 
1.28 and 1.63 years older at the time of stimulant treat-
ment compared with other socioeconomic groups.
Discussion
Our study found that prescription stimulants in WA 
varied significantly according to an individual’s coun-
try of birth. In particular, the odds of having stimulants 
in those born in Africa, Asia, Middle-East or South 
America were around one-half, and the mean age was 
2.7 years older than in those born in Australia, Europe or 
North America. These findings are consistent with those 
documented in the earlier Ghosh et al. [6] study where a 
cohort of people born in WA between 1980 and 2007 was 
followed through time to identify those who had a stimu-
lant record between 2003 and 2007 for ADHD treatment. 
That study employed a whole-population Australian birth 
cohort and used parental countries of birth as a proxy for 
ethnic groups, and so was not reliant on hospital admis-
sion for membership. The current study, on the other 
hand, had the advantage of including individuals born 
overseas, ascertained ethnic group using the individuals’ 
country of birth (not the parents). Our present results 
provide a validation of the earlier conclusions. The two 
different studies used cohorts constructed and meas-
ured in different ways, and were thus affected by different 
potential sources of error concerning external validity; 
yet the two studies have yielded similar results.
There were several limitations of the method used in 
this study. First, the individual’s country of birth variable 
was used as a surrogate given the absence of more direct 
ethnicity information. Groupings based on country of 
birth limited the capacity to detect differences between 
ethnicities and regional variations within countries to 
some extent, although it is generally agreed that coun-
try of birth plays a role in influencing individuals’ beliefs 
and attitudes. Second, detailed immigration information 
was unavailable and, therefore, we could not evaluate the 
association between stimulant use and refugee status or 
skilled migration. Third, our datasets did not allow us to 
identify anyone diagnosed with ADHD, yet not treated 
with stimulants. Fourth, as the stimulant data were only 
available from 2003, starting from initiation of the Stim-
ulant Regulatory Scheme in WA, the first record in the 
Table 2 Odds ratios for the association of at least one record of stimulant treatment for ADHD with cultural and demo-
graphic factors
a All parameters were included in this model so as to adjust each result for potential confounding by other covariates
b  Reference category
Risk factors Univariable Multivariablea
OR (95% CI) P value OR (95% CI) P value
HPNO/LPNO status
 HPNOb 1.00 1.00
 LPNO 0.51 (0.45–0.59) <0.001 0.53 (0.46–0.61) <0.001
Sex
 Maleb 1.00 1.00
 Female 0.32 (0.31–0.33) <0.001 0.31 (0.30–0.32) <0.001
Geographical remoteness
 Metropolitanb 1.00 1.00
 Rural 0.81 (0.78–0.85) <0.001 0.80 (0.77–0.84) <0.001
 Remote 0.44 (0.39–0.50) <0.001 0.43 (0.38–0.48) <0.001
Social disadvantage
 Least disadvantagedb 1.00 1.00
 Less disadvantaged 1.08 (1.01–1.15) <0.01 1.02 (0.96–1.10) 0.52
 Little disadvantaged 0.98 (0.91–1.05) 0.60 0.97 (0.90–1.04) 0.33
 More disadvantaged 1.05 (0.96–1.14) 0.30 1.02 (0.94–1.12) 0.60
 Most disadvantaged 0.99 (0.89–1.10) 0.78 0.96 (0.86–1.06) 0.41
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stimulant dataset might not have been the first stimulant 
record in an individual’s life. In the absence of informa-
tion prior to 2003, we were unable to observe the dura-
tion of stimulant treatment or dose information and, 
therefore, possible progression of ADHD symptoms in 
an individual’s life. Findings were further limited by the 
fact that records of dispensed prescription stimulant may 
not always determine the actual pattern of stimulant use 
for ADHD treatment, especially because there is a high 
prevalence of diversion and misuse of pharmaceutical 
stimulants among the adolescent and young adult stu-
dent populations with ADHD [17]. Nevertheless, our 
study contributes to emerging evidence of the existence 
of ethnic differences in stimulant use, as we attempt to 
understand how ADHD behaviour is conceptualised in 
cross-cultural settings.
The strengths of this study compared with previ-
ous published studies were the use of whole-population 
linked data on a study population of nearly 700,000; a 
study cohort representing approximately 40% of the WA 
population aged 0–25 years between 1980 and 2007; and 
use of a comparison group of people with no records of 
stimulant use for ADHD. Whilst the representativeness 
of our cohort and the purity of exposure contract were far 
from perfect, they were superior to what can be achieved 
in a clinic-based research setting where subjects are typi-
cally highly selected and their treatments obtained out-
side unreliably recorded.
Cultural attitude towards ADHD behaviour, and resist-
ance to accept a biomedical cause of ADHD and medi-
cation treatment are the prime reasons for a reduced 
likelihood of prescription stimulant and delayed onset of 
stimulant use among LPNO groups. Individuals’ percep-
tions of normal and pathological behaviour are largely 
determined by cultural beliefs which influence their 
care-seeking behaviour [18]. For example, ADHD behav-
iour was viewed by school teachers in India as childhood 
transition likely to improve as the child grew older [19]. 
The researcher reported that the ADHD behaviour was 
perceived by the teachers as a positive trait of a child 
with higher physical energy levels and cognitive abilities. 
This cultural complexity in understanding ADHD behav-
iour in Indian society was reported to lead to a 6-year 
gap between the noticing ADHD symptom and making 
a diagnosis [20]. Similarly, culture-specific differences in 
attitudes towards symptoms of ADHD were reported in 
Iranian culture, where ADHD was viewed as signs of nor-
mal child development and independence leading to at 
least a two-year delay in treatment [21]. Perceptual differ-
ences were also observed among Moroccan, Turkish and 
Surname immigrants in the Netherlands, with a higher 
treatment threshold for ADHD behaviour, resulting in 
a lower number of prescription medications in those 
immigrant children than in native Dutch children [22]. 
Willingness to prefer medication treatment for ADHD 
Table 3 Mean age in years in those receiving a stimulant medication for ADHD according to cultural and demographic 
factors
a  All parameters were included in this model so as to adjust each result for potential confounding by other covariates
b  Reference category
Predictors Univariable Multivariablea
Mean age Mean difference (95% CI) p value Mean age Mean difference (95% CI) p value
HPNO/LPNO status
 HPNOb 13.10 12.27
 LPNO 16.08 2.99 (2.29, 3.68) <0.001 14.98 2.72 (2.00, 3.431) <0.001
Sex
 Maleb 12.82 12.78
 Female 14.32 1.50 (1.30, 1.70) <0.001 14.47 1.70 (1.48, 1.90) <0.001
Geographical remoteness
 Metropolitanb 13.13 14.23
 Rural 12.07 −1.06 (−1.30, −0.83) <0.001 13.63 −0.60 (−0.84, −0.36) <0.001
 Remote 11.50 −1.63 (−2.24, −1.02) <0.001 13.01 −1.21 (−1.82, −0.61) <0.001
Social disadvantage
 Least disadvantagedb 13.65 14.83
 Less disadvantaged 12.18 −1.47 (−1.70, −1.26) <0.001 13.54 −1.28 (−1.50, −1.07) <0.001
 Little disadvantaged 12.03 −1.62 (−1.93, −1.31) <0.001 13.38 −1.45 (−1.76, −1.14) <0.001
 More disadvantaged 11.82 −1.83 (−2.27, −1.40) <0.001 13.17 −1.65 (−2.09, −1.22) <0.001
 Most disadvantaged 11.85 −1.80 (−2.14, −1.47) <0.001 13.20 −1.63 (−1.96, −1.29) <0.001
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behaviour is a pivotal cultural question that needs to be 
investigated.
Lower rates of medication treatment and delay in treat-
ment were documented among Latino adolescents and 
youth in Venezuela largely due to a reluctance to accept 
medication treatment [23]. Research suggested that cultural 
beliefs about the aetiology of ADHD influenced African–
American and Latino communities to pursue alternative 
forms of treatment or decide not to pursue treatment at all 
[24]. Even when they accepted biomedical causes of ADHD, 
behavioural intervention was their preferred method of 
treatment rather than stimulant medication [25]. Substan-
tial ethnic disparities continue to exist for stimulant treat-
ment of ADHD and other mental and behavioural problems 
in Netherlands [26], Spain [27] and Sweden [28].
Our findings also revealed that males were 69% more 
likely to receive stimulant than females possibly due to 
gender variation in ADHD manifestations, where boys 
exhibit more hyperactivity than girls, who display mostly 
inattentiveness [29]. As ADHD is considered a disorder 
of academic performance, excitability may cause dis-
ruption in a classroom situation, resulting in frequent 
diagnosis referrals and subsequent treatment in boys 
sometime even without valid cause [30]. While a high 
stimulant prevalence in boys is widely reported, a grow-
ing number of girls are being medicated for ADHD, lead-
ing to a declining male:female ratio in Australia [31].
We found individuals living in the metropolitan areas 
were more likely to have prescription stimulants. Studies 
have examined differential healthcare access, availability 
of physicians and ready access to healthcare services in 
major cities as factors influencing regional variation in 
stimulant treatment [32]. Differences in beliefs and val-
ues about child behaviour and medical treatment, and 
the willingness to accept stimulant treatment may also 
vary geographically, contributing to a regional disparity 
[33]. The older age at commencement of stimulants in 
the metropolitan area than in rural areas in our results is 
a more difficult finding to explain. It may reflect a differ-
ence between metro and rural in the use of medication 
to improve academic outcomes, more so than to allevi-
ate disruptive behaviours [34] as those affected were 
aged more into their teenage years. A positive correlation 
between lower socioeconomic status and higher psycho-
stimulant treatment has been documented previously in 
national and international studies [35, 36]. Due to large 
socioeconomic discrepancies in stimulant use, some 
studies have uncovered concerns that psychosocial issues 
associated with socioeconomic disadvantage may be 
misattributed as symptoms of ADHD in children, leading 
to suggestions that medicalising behaviour, that might 
have been considered normal in the past, is a popular 
global phenomenon [37, 38].
Conclusions
Using a different method, this study validated cultural 
differences in stimulant treatment for ADHD reported 
in previous research, and identified significant country 
of birth variations, as well as gender, regional and socio-
economic disparities in stimulant use for ADHD in WA. 
Individuals born in Africa, Asia, Middle-East or South-
America were less likely to have stimulant treatment than 
individuals born in Australia/New Zealand, Europe or 
North America. A greater likelihood of stimulant treat-
ment among boys, individuals living in metropolitan 
areas, and living with socioeconomic disadvantage was 
also observed. The findings highlight the need for tai-
loring ADHD diagnosis, treatments and service delivery 
appropriately to children and adolescents from diverse 
cultures.
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